Adsorbers for Selective Removal of Extra Domain A-fibronectin from Patient PlasmaMiyamoto K*, Hirukawa M, Komai T and Horiuchi T
Division of Chemistry for Materials, Graduate School of Engineering, Mie University, 1577, Kurima-machiya-cho, Tsu, Mie, 514-8507, Japan
- *Corresponding Author:
- Miyamoto K
Division of Chemistry for Materials, Graduate School of Engineering
Mie University, 1577, Kurima-machiya-cho, Tsu, Mie, 514-8507, Japan
Tel: +81 -59-231-9480
Fax: +81 -59-231-9480
E-mail: [email protected]
Received date: May 15, 2017; Accepted date: May 24, 2017; Published date: May 29, 2017
Citation: Miyamoto K, Hirukawa M, Komai T, Horiuchi T (2017) Adsorbers for Selective Removal of Extra Domain A-fibronectin from Patient Plasma. Fibrom Open Access 2:122.
Copyright: © 2017 Miyamoto K. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
In patients with collagen diseases such as rheumatoid arthritis and systemic lupus erythematosus, immune complexes circulate in the blood deposits on tissues, causing inflammation, sclerosis, and deformable symptoms accompanying joint pain. These complexes form cryogels on cooling and can be removed by cryofiltration therapy. Fibronectin in the blood is a mediator of vascular inflammation and its levels are elevated in patients with fibromyalgia. In particular, the extra domain A containing FN (EDA-FN), which is important for cryogel formation, occurs in high concentration in the plasma of patients with rheumatoid arthritis. Gellan sulfate (GS) was developed to selectively remove EDA-FN from blood. Removal of EDA-FN with GS could be effective for suppressing inflammation caused by immune complex deposition such as in autoimmune disease and IgA nephropathy.